From Pharmacia's pnu.com
Celebrex, the number-one selling prescription arthritis medication worldwide, had sales of $687 million
in the quarter and $1.8 billion in the first nine months. In the U.S., sales for the quarter were $584
million with a slightly positive impact from anticipatory purchasing at the trade level. During the third
quarter, the European rollout of Celebrex continued with launches in Italy and Spain.
Assuming 4Q sales = 3Q sales, then forecasting full year sales for Celebrex, Pharmacia can boast Y2000 sales of at lease $2.5Billion.
Pharmacia's year end results should be out within the next couple of weeks.
Compare this to Merck's VIOXX achieved
$2.2 billion in sales for the full year 2000, with $700 million in the fourth quarter.
As I understand, both these companies are still ramping up sales to more nations.
Wow, Pennsaid gets to rumble in a $4.7 Billion sand box! So every 1% market share we earn/win/steal/get is $48,000,000 usd. And according to Wolf, "a growing OA market."
Let's get it on!!! |
